Associated High Confidence AOPs |
---|
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:16 | Acetylcholinesterase inhibition leading to acute mortality | Unclassified | Under Development | 0.29 | KE:445 | Respiratory distress/arrest |
KE:1703 | Dysregulation of heart rate and vascular tone | |||||
AOP:21 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 | Unclassified | WPHA/WNT Endorsed | 0.2 | KE:317 | Altered, Cardiovascular development/function |
AOP:27 | Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) | Gastrointestinal System Disease | Under Development | 0.12 | KE:1115 | Increase, Reactive oxygen species |
AOP:37 | PPARα activation leading to hepatocellular adenomas and carcinomas in rodents | Cancer; Gastrointestinal System Disease | Under Development | 0.2 | KE:716 | Increase, cell proliferation (hepatocytes) |
AOP:39 | Covalent Binding, Protein, leading to Increase, Allergic Respiratory Hypersensitivity Response | Respiratory System Disease | Under Development | 0.2 | KE:272 | Activation/Proliferation, T-cells |
AOP:41 | Sustained AhR Activation leading to Rodent Liver Tumours | Cancer; Gastrointestinal System Disease | Under Review | 0.4 | KE:854 | Alterations, Cellular proliferation / hyperplasia |
KE:853 | Changes/Inhibition, Cellular Homeostasis and Apoptosis | |||||
AOP:64 | Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility | Reproductive System Disease | - | 0.14 | KE:496 | Increased apoptosis, decreased fetal/adult Leydig Cells |
AOP:77 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony death/failure 1 | Unclassified | - | 0.14 | KE:341 | Impairment, Learning and memory |
AOP:78 | Nicotinic acetylcholine receptor activation contributes to abnormal role change within the worker bee caste leading to colony death failure 1 | Unclassified | - | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:87 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure | Unclassified | - | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:88 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure via abnormal role change within caste | Unclassified | - | 0.14 | KE:341 | Impairment, Learning and memory |
AOP:89 | Nicotinic acetylcholine receptor activation followed by desensitization contributes to abnormal foraging and directly leads to colony loss/failure | Unclassified | - | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:90 | Nicotinic acetylcholine receptor activation contributes to abnormal roll change within the worker bee caste leading to colony loss/failure 2 | Unclassified | - | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:94 | Sodium channel inhibition leading to congenital malformations | Unclassified | - | 0.17 | KE:445 | Respiratory distress/arrest |
AOP:99 | Histamine (H2) receptor antagonism leading to reduced survival | Unclassified | - | 0.14 | KE:341 | Impairment, Learning and memory |
AOP:105 | Alpha2u-microglobulin cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary System Disease | - | 0.17 | KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) |
AOP:107 | Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat | Cancer; Gastrointestinal System Disease | Under Review | 0.2 | KE:716 | Increase, cell proliferation (hepatocytes) |
AOP:110 | Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine System Disease | - | 0.14 | KE:739 | Increase, Hypertrophy and proliferation (follicular cell) |
AOP:114 | HPPD inhibition leading to corneal papillomas and carcinomas (in rat) | Cancer | - | 0.17 | KE:778 | Increase, Regenerative cell proliferation (corneal cells) |
AOP:115 | Epithelial cytotoxicity leading to forestomach tumors (in mouse and rat) | Cancer | - | 0.2 | KE:781 | Increase, Regenerative cell proliferation (forestomach epithelial cells) |
AOP:116 | Cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary System Disease | - | 0.25 | KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) |
AOP:117 | Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | Under Development | 0.25 | KE:716 | Increase, cell proliferation (hepatocytes) |
AOP:118 | Chronic cytotoxicity leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | - | 0.25 | KE:787 | Increase, Regenerative cell proliferation (hepatocytes) |
AOP:119 | Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine System Disease | - | 0.14 | KE:739 | Increase, Hypertrophy and proliferation (follicular cell) |
AOP:121 | Urinary bladder calculi leading to urothelial papillomas and carcinomas (in mouse and rat) | Cancer; Urinary System Disease | - | 0.2 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
AOP:136 | Intracellular Acidification Induced Olfactory Epithelial Injury Leading to Site of Contact Nasal Tumors | Benign Neoplasm; Respiratory System Disease | Under Review | 0.14 | KE:870 | Increase, Cell Proliferation |
AOP:150 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF | Unclassified | WPHA/WNT Endorsed | 0.14 | KE:317 | Altered, Cardiovascular development/function |
AOP:164 | Beta-2 adrenergic agonist activity leading to mesovarian leiomyomas in the rat and mouse | Cancer; Reproductive System Disease | - | 0.17 | KE:1042 | Proliferation/Clonal Expansion, smooth muscle |
AOP:167 | Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. | Reproductive System Disease; Cancer | - | 0.14 | KE:1067 | Proliferation/Clonal Expansion, aberrant basal cells |
AOP:207 | NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans | Reproductive System Disease | - | 0.25 | KE:1115 | Increase, Reactive oxygen species |
KE:1262 | Apoptosis | |||||
AOP:212 | Histone deacetylase inhibition leading to testicular atrophy | Reproductive System Disease | WPHA/WNT Endorsed | 0.17 | KE:1262 | Apoptosis |
AOP:213 | Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH) | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP:220 | Cyp2E1 Activation Leading to Liver Cancer | Cancer; Gastrointestinal System Disease | WPHA/WNT Endorsed | 0.2 | KE:1394 | Induction, persistent proliferation/sustained proliferation |
AOP:286 | Mitochondrial complex III antagonism leading to growth inhibition (1) | Unclassified | - | 0.25 | KE:1821 | Decrease, Cell proliferation |
AOP:290 | Mitochondrial ATP synthase antagonism leading to growth inhibition (1) | Unclassified | - | 0.25 | KE:1821 | Decrease, Cell proliferation |
AOP:299 | Deposition of energy leading to population decline via DNA oxidation and follicular atresia | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species |
AOP:311 | Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species |
AOP:335 | AOP for urothelial carcinogenesis due to chemical cytotoxicity by mitochondrial impairment | Cancer; Urinary System Disease | - | 0.2 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
AOP:362 | Immune mediated hepatitis | Gastrointestinal System Disease; Immune System Disease | - | 0.12 | KE:1818 | Immune cell activation |
AOP:379 | Binding to ACE2 leading to thrombosis and disseminated intravascular coagulation | Cardiovascular System Disease | Under Development | 0.14 | KE:1869 | Diminished protective oxidative stress response |
AOP:383 | Inhibition of Angiotensin-converting enzyme 2 leading to liver fibrosis | Gastrointestinal System Disease | Under Development | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP:384 | Hyperactivation of ACE/Ang-II/AT1R axis leading to chronic kidney disease | Urinary System Disease | - | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP:386 | Deposition of ionizing energy leading to population decline via inhibition of photosynthesis | Reproductive System Disease | - | 0.12 | KE:1115 | Increase, Reactive oxygen species |
AOP:387 | Deposition of ionising energy leading to population decline via mitochondrial dysfunction | Reproductive System Disease | - | 0.12 | KE:1115 | Increase, Reactive oxygen species |
AOP:399 | Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos) | Unclassified | - | 0.12 | KE:1821 | Decrease, Cell proliferation |
AOP:406 | SARS-CoV-2 infection leading to hyperinflammation | Unclassified | - | 0.17 | KE:1869 | Diminished protective oxidative stress response |
AOP:409 | Frustrated phagocytosis leads to malignant mesothelioma | Cancer | - | 0.38 | KE:1115 | Increase, Reactive oxygen species |
KE:870 | Increase, Cell Proliferation | |||||
KE:1669 | Increased, DNA damage and mutation | |||||
AOP:413 | Oxidation and antagonism of reduced glutathione leading to mortality via acute renal failure | Unclassified | - | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP:432 | Deposition of Energy by Ionizing Radiation leading to Acute Myeloid Leukemia | Hematopoietic System Disease; Cancer | - | 0.09 | KE:870 | Increase, Cell Proliferation |
AOP:439 | Activation of the AhR leading to metastatic breast cancer | Thoracic Disease; Cancer | Under Development | 0.11 | KE:1262 | Apoptosis |
AOP:441 | Ionizing radiation-induced DNA damage leads to microcephaly via apoptosis and premature cell differentiation | Congenital Nervous System Abnormality; Nervous System Disease | - | 0.14 | KE:1262 | Apoptosis |
AOP:452 | Adverse outcome pathway of PM-induced respiratory toxicity | Respiratory System Disease | - | 0.09 | KE:1262 | Apoptosis |
AOP:456 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity | Unclassified | Under Review | 0.17 | KE:317 | Altered, Cardiovascular development/function |
AOP:460 | Antagonism of Smoothened receptor leading to orofacial clefting | Unclassified | Under Development | 0.22 | KE:1821 | Decrease, Cell proliferation |
KE:1262 | Apoptosis | |||||
AOP:478 | Deposition of energy leading to occurrence of cataracts | Nervous System Disease; Monogenic Disease | Under Review | 0.2 | KE:870 | Increase, Cell Proliferation |
KE:1636 | Increase, Chromosomal aberrations | |||||
AOP:491 | Decrease, GLI1/2 target gene expression leads to orofacial clefting | Unclassified | Under Development | 0.33 | KE:1821 | Decrease, Cell proliferation |
KE:1262 | Apoptosis | |||||
AOP:492 | Glutathione conjugation leading to reproductive dysfunction via oxidative stress | Reproductive System Disease | - | 0.2 | KE:1115 | Increase, Reactive oxygen species |
AOP:495 | Androgen receptor activation leading to prostate cancer | Reproductive System Disease; Cancer | - | 0.22 | KE:854 | Alterations, Cellular proliferation / hyperplasia |
KE:1183 | Decreased, Apoptosis (Epithelial Cells) | |||||
AOP:497 | ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome | Inherited Metabolic Disorder; Disease Of Metabolism | - | 0.12 | KE:1115 | Increase, Reactive oxygen species |
AOP:521 | Essential element imbalance leads to reproductive failure via oxidative stress | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species |
AOP:563 | Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis | Reproductive System Disease; Endocrine System Disease | - | 0.17 | KE:1262 | Apoptosis |
AOP:569 | Decreased DNA methylation of FAM50B/PTCHD3 leading to IQ loss of children via PI3K-Akt pathway | Developmental Disorder Of Mental Health | - | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:12 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging | Nervous System Disease; Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:13 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.1 | KE:341 | Impairment, Learning and memory |
AOP:17 | Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.1 | KE:341 | Impairment, Learning and memory |
AOP:40 | Covalent Protein binding leading to Skin Sensitisation | Integumentary System Disease | WPHA/WNT Endorsed | 0.4 | KE:827 | sensitisation, skin |
KE:272 | Activation/Proliferation, T-cells | |||||
AOP:48 | Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment. | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.11 | KE:341 | Impairment, Learning and memory |
AOP:54 | Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.1 | KE:341 | Impairment, Learning and memory |
AOP:109 | Cytotoxicity leading to bronchioloalveolar adenomas and carcinomas (in mouse) | Cancer; Respiratory System Disease | - | 0.4 | KE:736 | Increase, Adenomas/carcinomas (bronchioloalveolar) |
KE:734 | Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) | |||||
AOP:139 | Alkylation of DNA leading to cancer 1 | Cancer | - | 0.25 | KE:885 | Increase, Cancer |
AOP:148 | EGFR Activation Leading to Decreased Lung Function | Respiratory System Disease | Under Development | 0.25 | KE:1250 | Decrease, Lung function |
AOP:149 | Peptide Oxidation Leading to Hypertension | Cardiovascular System Disease | Under Development | 0.1 | KE:952 | Hypertension |
AOP:173 | Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis | Musculoskeletal System Disease; Respiratory System Disease | WPHA/WNT Endorsed | 0.12 | KE:1458 | Pulmonary fibrosis |
AOP:205 | AOP from chemical insult to cell death | Unclassified | - | 0.17 | KE:1262 | Apoptosis |
AOP:206 | Peroxisome proliferator-activated receptors γ inactivation leading to lung fibrosis | Musculoskeletal System Disease; Respiratory System Disease | Under Development | 0.17 | KE:1276 | Lung fibrosis |
AOP:241 | Latent Transforming Growth Factor beta1 activation leads to pulmonary fibrosis | Musculoskeletal System Disease; Respiratory System Disease | - | 0.17 | KE:1458 | Pulmonary fibrosis |
AOP:272 | Deposition of energy leading to lung cancer | Cancer | WPHA/WNT Endorsed | 0.43 | KE:870 | Increase, Cell Proliferation |
KE:1556 | Increase, lung cancer | |||||
KE:1636 | Increase, Chromosomal aberrations | |||||
AOP:293 | Increased DNA damage leading to increased risk of breast cancer | Genetic Disease; Thoracic Disease; Cancer | Under Development | 0.22 | KE:1193 | N/A, Breast Cancer |
KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | |||||
AOP:294 | Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer | Genetic Disease; Thoracic Disease; Cancer | Under Development | 0.22 | KE:1193 | N/A, Breast Cancer |
KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | |||||
AOP:296 | Oxidative DNA damage leading to chromosomal aberrations and mutations | Genetic Disease; Chromosomal Disease | WPHA/WNT Endorsed | 0.2 | KE:1636 | Increase, Chromosomal aberrations |
AOP:302 | Lung surfactant function inhibition leading to decreased lung function | Respiratory System Disease | Under Development | 0.2 | KE:1250 | Decrease, Lung function |
AOP:303 | Frustrated phagocytosis-induced lung cancer | Cancer | Under Development | 0.57 | KE:1669 | Increased, DNA damage and mutation |
KE:870 | Increase, Cell Proliferation | |||||
KE:1670 | Lung cancer | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
AOP:347 | Toll-like receptor 4 activation and peroxisome proliferator-activated receptor gamma inactivation leading to pulmonary fibrosis | Musculoskeletal System Disease; Respiratory System Disease | - | 0.11 | KE:1458 | Pulmonary fibrosis |
AOP:382 | Angiotensin II type 1 receptor (AT1R) agonism leading to lung fibrosis | Musculoskeletal System Disease; Respiratory System Disease | Under Development | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:1276 | Lung fibrosis | |||||
AOP:411 | Oxidative stress Leading to Decreased Lung Function | Respiratory System Disease | - | 0.25 | KE:1250 | Decrease, Lung function |
AOP:414 | Aryl hydrocarbon receptor activation leading to lung fibrosis through TGF-β dependent fibrosis toxicity pathway | Musculoskeletal System Disease; Respiratory System Disease | - | 0.2 | KE:1276 | Lung fibrosis |
AOP:415 | Aryl hydrocarbon receptor activation leading to lung fibrosis through IL-6 toxicity pathway | Musculoskeletal System Disease; Respiratory System Disease | - | 0.2 | KE:1276 | Lung fibrosis |
AOP:416 | Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway | Cancer | - | 0.5 | KE:1669 | Increased, DNA damage and mutation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1670 | Lung cancer | |||||
AOP:417 | Aryl hydrocarbon receptor activation leading to lung cancer through AHR-ARNT toxicity pathway | Cancer | - | 0.4 | KE:1669 | Increased, DNA damage and mutation |
KE:1670 | Lung cancer | |||||
AOP:418 | Aryl hydrocarbon receptor activation leading to impaired lung function through AHR-ARNT toxicity pathway | Respiratory System Disease | - | 0.4 | KE:1115 | Increase, Reactive oxygen species |
KE:1250 | Decrease, Lung function | |||||
AOP:419 | Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathway | Respiratory System Disease | - | 0.5 | KE:1250 | Decrease, Lung function |
KE:1262 | Apoptosis | |||||
AOP:420 | Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathway | Cancer | - | 0.5 | KE:870 | Increase, Cell Proliferation |
KE:1670 | Lung cancer | |||||
AOP:424 | Oxidative stress Leading to Decreased Lung Function via CFTR dysfunction | Respiratory System Disease | - | 0.17 | KE:1250 | Decrease, Lung function |
AOP:425 | Oxidative Stress Leading to Decreased Lung Function via Decreased FOXJ1 | Respiratory System Disease | - | 0.17 | KE:1250 | Decrease, Lung function |
AOP:451 | Interaction with lung resident cell membrane components leads to lung cancer | Cancer | - | 0.44 | KE:1669 | Increased, DNA damage and mutation |
KE:870 | Increase, Cell Proliferation | |||||
KE:1670 | Lung cancer | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
AOP:474 | Succinate dehydrogenase inactivation leads to cancer by promoting EMT | Cancer | Under Development | 0.2 | KE:885 | Increase, Cancer |
AOP:475 | Binding of chemicals to ionotropic glutamate receptors leads to impairment of learning and memory via loss of drebrin from dendritic spines of neurons | Developmental Disorder Of Mental Health | Under Development | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:483 | Deposition of Energy Leading to Learning and Memory Impairment | Developmental Disorder Of Mental Health | Under Review | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:490 | Co-activation of IP3R and RyR leads to reduced IQ through non-cholinergic mechanisms | Developmental Disorder Of Mental Health | - | 0.09 | KE:341 | Impairment, Learning and memory |
AOP:493 | ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity | Acquired Metabolic Disease | - | 0.1 | KE:2129 | Metabolically unhealthy Obesity |
AOP:498 | Increased LCN2/iron complex leading to neurological disorders | Nervous System Disease | - | 0.25 | KE:2150 | Neurological disorder |
AOP:499 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via disrupted neurotransmitter release | Developmental Disorder Of Mental Health | - | 0.25 | KE:341 | Impairment, Learning and memory |
AOP:500 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis | Developmental Disorder Of Mental Health | - | 0.43 | KE:1115 | Increase, Reactive oxygen species |
KE:1262 | Apoptosis | |||||
KE:341 | Impairment, Learning and memory | |||||
AOP:501 | Excessive iron accumulation leading to neurological disorders | Nervous System Disease | - | 0.25 | KE:2150 | Neurological disorder |
AOP:520 | Retinoic acid receptor agonism during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.2 | KE:341 | Impairment, Learning and memory |
AOP:525 | Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.08 | KE:341 | Impairment, Learning and memory |
AOP:533 | Retinoic acid receptor antagonism during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.17 | KE:341 | Impairment, Learning and memory |
AOP:534 | Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress | Cancer | - | 0.5 | KE:1115 | Increase, Reactive oxygen species |
KE:885 | Increase, Cancer | |||||
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental Disorder Of Mental Health | - | 0.22 | KE:1262 | Apoptosis |
KE:341 | Impairment, Learning and memory | |||||
AOP:546 | Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms | Cancer | - | 0.2 | KE:885 | Increase, Cancer |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:263 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation | Unclassified | WPHA/WNT Endorsed | 0.5 | KE:1821 | Decrease, Cell proliferation |
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:264 | Uncoupling of oxidative phosphorylation leading to growth inhibition via ATP depletion associated cell death | Unclassified | Under Development | 0.25 | KE:1446 | Decrease, Coupling of oxidative phosphorylation |
AOP:265 | Uncoupling of oxidative phosphorylation leading to growth inhibition via increased cytosolic calcium | Unclassified | Under Development | 0.25 | KE:1446 | Decrease, Coupling of oxidative phosphorylation |
AOP:266 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased Na-K ATPase activity | Unclassified | Under Development | 0.17 | KE:1446 | Decrease, Coupling of oxidative phosphorylation |
AOP:267 | Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion | Unclassified | Under Development | 0.4 | KE:1821 | Decrease, Cell proliferation |
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:268 | Uncoupling of oxidative phosphorylation leading to growth inhibition via mitochondrial swelling | Unclassified | Under Development | 0.25 | KE:1446 | Decrease, Coupling of oxidative phosphorylation |
AOP:282 | Adverse outcome pathway on photochemical toxicity initiated by light exposure | Unclassified | Under Review | 0.25 | KE:1115 | Increase, Reactive oxygen species |
AOP:298 | Increase in reactive oxygen species (ROS) leading to human treatment-resistant gastric cancer via chronic ROS | Cancer; Gastrointestinal System Disease | Under Review | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:1753 | Chronic reactive oxygen species | |||||
AOP:324 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell death | Unclassified | - | 0.25 | KE:1115 | Increase, Reactive oxygen species |
AOP:325 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death | Unclassified | - | 0.25 | KE:1115 | Increase, Reactive oxygen species |
AOP:326 | Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell death | Unclassified | - | 0.25 | KE:1115 | Increase, Reactive oxygen species |
AOP:327 | Excessive reactive oxygen species production leading to mortality (1) | Unclassified | - | 0.2 | KE:1115 | Increase, Reactive oxygen species |
AOP:328 | Excessive reactive oxygen species production leading to mortality (2) | Unclassified | - | 0.2 | KE:1115 | Increase, Reactive oxygen species |
AOP:329 | Excessive reactive oxygen species production leading to mortality (3) | Unclassified | - | 0.2 | KE:1115 | Increase, Reactive oxygen species |
AOP:330 | Excessive reactive oxygen species production leading to mortality (4) | Unclassified | - | 0.2 | KE:1115 | Increase, Reactive oxygen species |
AOP:331 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and reduced cell proliferation | Unclassified | - | 0.33 | KE:1821 | Decrease, Cell proliferation |
KE:1115 | Increase, Reactive oxygen species | |||||
AOP:332 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell proliferation | Unclassified | - | 0.4 | KE:1821 | Decrease, Cell proliferation |
KE:1115 | Increase, Reactive oxygen species | |||||
AOP:333 | Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation | Unclassified | - | 0.6 | KE:1821 | Decrease, Cell proliferation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:423 | Toxicological mechanisms of hepatocyte apoptosis through the PARP1 dependent cell death pathway | Unclassified | - | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP:438 | reactive oxygen species generation leading to increased cardiovascular morbidity and mortality | Cardiovascular System Disease | - | 0.08 | KE:1115 | Increase, Reactive oxygen species |
AOP:443 | DNA damage and mutations leading to Metastatic Breast Cancer | Thoracic Disease; Cancer | Under Development | 0.1 | KE:1669 | Increased, DNA damage and mutation |
AOP:446 | PM-related Adverse outcome pathway frameworks on various systems | Respiratory System Disease | - | 0.25 | KE:1262 | Apoptosis |
KE:1458 | Pulmonary fibrosis | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1250 | Decrease, Lung function | |||||
KE:1993 | Increase, Pneumonia | |||||
AOP:448 | ROS, inflammation, and activation of nAChR lead to increased incidence of cardiovascular morbidity and mortality | Cardiovascular System Disease | - | 0.06 | KE:1115 | Increase, Reactive oxygen species |
AOP:453 | Reactive oxygen species and subsequent oxidative stress lead to increased incidence of digestive morbidity and mortality in the general population | Gastrointestinal System Disease | - | 0.08 | KE:1115 | Increase, Reactive oxygen species |
AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal System Disease | - | 0.18 | KE:1115 | Increase, Reactive oxygen species |
KE:1262 | Apoptosis | |||||
AOP:469 | Reactive oxygen speicies overproduction leading to increased digestive morbidity and mortality in generation population | Gastrointestinal System Disease | - | 0.08 | KE:1115 | Increase, Reactive oxygen species |
AOP:472 | DNA adduct formation leading to kidney failure | Urinary System Disease | - | 0.11 | KE:1115 | Increase, Reactive oxygen species |
AOP:488 | Increased reactive oxygen species production leading to decreased cognitive function | Cognitive Disorder | - | 0.29 | KE:1115 | Increase, Reactive oxygen species |
KE:1869 | Diminished protective oxidative stress response | |||||
AOP:511 | The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects | Cardiovascular System Disease | - | 0.06 | KE:1115 | Increase, Reactive oxygen species |
AOP:540 | Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production | Unclassified | - | 0.22 | KE:1115 | Increase, Reactive oxygen species |
KE:1262 | Apoptosis | |||||
AOP:541 | Excessive ROS generation leading to increased incidence of vascular calcification by VSMC phenotype switching | Cardiovascular System Disease | - | 0.08 | KE:1115 | Increase, Reactive oxygen species |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | 0.4 | KE:1115 | Increase, Reactive oxygen species |
KE:885 | Increase, Cancer | |||||
AOP:513 | Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway | Cancer | - | 0.4 | KE:1115 | Increase, Reactive oxygen species |
KE:885 | Increase, Cancer |
TICToK is a database of tattoo ink chemicals compiled from different regulatory resources. The authors are not liable for any inaccuracies or omissions of any chemicals in this resource. Importantly, our sole goal to build this resource on tattoo ink chemicals is to enable future basic research on this topic, and it does not necessarily reflect the views or objectives of our employers or funders.